Pfizer Settles Viagra Patent Litigation With Teva…Bit of a Letdown

NEW YORK, Dec 17, 2013 (BUSINESS WIRE) — Pfizer Inc. announced that it has settled its litigation against Teva Pharmaceuticals, USA Inc., relating to Pfizer’s patent covering the use of Viagra(R) to treat erectile dysfunction (sildenafil citrate 25, 50, and 100 mg tablets), which expires in April 2020 (including pediatric exclusivity). As a result of the settlement, Teva will be allowed to launch a generic version of Viagra(R) in the United States on December 11, 2017, or earlier under certain circumstances. Teva will pay Pfizer a royalty for a license to produce its generic version. The terms of the settlement agreement are otherwise confidential. Teva has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of Viagra(R).

Teva obtains a licence to launch before patent term runs out. Pediatiric exclusivity? What are kids taking this for?

ISRAEL’S LEADING IP BLOG

PCTea-Bags

Patents in general and PCT applications in particular are often filed at the last minute causing stress. The need to meet tight deadlines threatens quality.

IP Factor has built our reputation by meeting deadlines with high quality applications at fair prices.

We now share our secret with the profession: PCTeabags – a carefully blended mixture of plant extracts that, when infused, relaxes the IP practitioner, taling the stress out of protecting intellectual property assets.

Also good for treating stress symptoms caused by patent drafting, design and trademark registration and enforcement.